Kim, Sohn G.
Becattini, Simone
Moody, Thomas U.
Shliaha, Pavel V.
Littmann, Eric R.
Seok, Ruth
Gjonbalaj, Mergim
Eaton, Vincent
Fontana, Emily
Amoretti, Luigi
Wright, Roberta
Caballero, Silvia
Wang, Zhong-Min X.
Jung, Hea-Jin
Morjaria, Sejal M.
Leiner, Ingrid M.
Qin, Weige
Ramos, Ruben J. J. F.
Cross, Justin R.
Narushima, Seiko
Honda, Kenya
Peled, Jonathan U.
Hendrickson, Ronald C.
Taur, Ying
van den Brink, Marcel R. M.
Pamer, Eric G.
Article History
Received: 22 October 2018
Accepted: 22 July 2019
First Online: 21 August 2019
Competing interests
: K.H. is co-founder and scientific advisor to Vedanta Biosciences. M.R.M.v.d.B. is on the advisory board of and has financial holdings in Seres Therapeutics Inc., serves on the DKMS medical council, has received speaker honoraria from Merck and Acute Leukemia Forum, holds patents that receive royalties from Seres Therapeutics Inc., has received honorarium and research support (1 January 2017 to present) from Seres Therapeutic Inc., and IP licensing with Seres Therapeutics Inc. and Juno. J.U.P. reports research funding, intellectual property fees, and travel reimbursement from Seres Therapeutics. E.G.P. has received speaker honoraria from Bristol-Myer Squibb, Celgene, Seres Therapeutics, MedImmune, Novartis, and Ferring Pharmaceuticals; is an inventor on patent application no. WPO2015179437A1, entitled ‘Methods and compositions for reducing <i>Clostridium difficile</i> infection’ and no. WPO2017091753A1, entitled ‘Methods and compositions for reducing vancomycin-resistant <i>Enterococci</i> infection or colonization’; and holds patents that receive royalties from Seres Therapeutics Inc.